Long-Term Antibody Response against SARS-CoV-2 in Health Care Workers: Effectiveness of Homologous and Heterologous Regimens and Their Relation to Systemic Vaccine-Associated Symptoms.

Vaccines (Basel) · 2022 · PMC9611514 · PMID 36298464

Europe PMC DOI

hedged sentence

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantp < 0.000001actually significant

In pairwise comparison, no difference in VAS between Pfizer and Moderna was found ( p = 0.49), whereas the difference in VAS between both the Pfizer and AstraZeneca vaccine and the Moderna and AstraZeneca vaccine were highly significant (for both pairwise comparisons p < 0.000001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.